Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study-Reference-Cited by-同舟云学术

Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study

Published:2023-08-17 Issue:8 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Almangour Thamer A.¹^ORCID,Ghonem Leen²,Alassiri Dareen¹,Aljurbua Alanoud¹,Al Musawa Mohammed³,Alharbi Aminah³,Almohaizeie Abdullah⁴⁵,Almuhisen Sara⁶,Alghaith Jeelan⁴,Damfu Nader⁷⁸,Aljefri Doaa⁹⁷,Alfahad Wafa¹⁰,Khormi Yaqoub¹⁰,Alanazi Menyfah Q.⁷¹¹,Alsowaida Yazed Saleh¹²^ORCID

Affiliation:

1. Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

2. Clinical Pharmacy Services, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia

3. Pharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia

4. Pharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

5. College of Pharmacy, Alfaisal University, Riyadh, Saudi Arabia

6. Pharmacy services administration, King Fahad Medical City, Riyadh, Saudi Arabia

7. King Abdullah International Medical Research Centre, Riyadh, Saudi Arabia

8. Infection Prevention and Control Department, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia

9. Pharmaceutical Care Department, King Abdul Aziz Medical City, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia

10. Pharmacy services, Prince Sultan Military Medical City, Riyadh, Saudi Arabia

11. King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

12. Department of Clinical Pharmacy, College of Pharmacy, Hail University, Hail, Saudi Arabia

Abstract

Ceftolozane-tazobactam (C-T) and ceftazidime-avibactam (CAZ-AVI) are two novel antimicrobials that retain activity against resistant Pseudomonas aeruginosa . The comparative effectiveness and safety of C-T versus CAZ-AVI remain unknown.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00405-23

Reference34 articles.

1. Approach to the Treatment of Patients with Serious Multidrug‐Resistant Pseudomonas aeruginosa Infections

2. Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997–2016

3. WHO. 2017. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research discovery and development of new antibiotics. Available at: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. Accessed 18 June 2022.

4. Employment of Mapping Technology in Antimicrobial Resistance Reporting in Saudi Arabia

5. Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel β-lactam-β-lactamase inhibitors as monotherapy versus combination for the treatment of drug-resistant Pseudomonas aeruginosa infections: A multicenter cohort study;Journal of Infection and Chemotherapy;2024-10

2. Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa;Journal of Antimicrobial Chemotherapy;2024-09-11

3. Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam;Antimicrobial Agents and Chemotherapy;2024-09-04

4. Ceftazidime-avibactam versus other antimicrobial agents for treatment of Multidrug-resistant Pseudomonas aeruginosa: a systematic review and meta-analysis;Infection;2024-08-24

5. Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy;Antibiotics;2024-07-26